(3.226.251.81) 您好!臺灣時間:2019/08/21 04:48
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
本論文永久網址: 
line
研究生:黃梓甯
研究生(外文):Tzu-Ning Huang
論文名稱:牛樟芝輔助肝癌化學治療與改善抗藥性表現之藥理活性暨分子機制探討
論文名稱(外文):Studies on Adjuvant Mechanism of Antrodia Camphorate Mycelia with Chemotherapy on Multidrug Resistance from Human Hepatoma Cells
指導教授:褚俊傑褚俊傑引用關係
指導教授(外文):Jiunn-Jye Chuu
學位類別:碩士
校院名稱:南台科技大學
系所名稱:生物科技系
學門:生命科學學門
學類:生物科技學類
論文出版年:2006
畢業學年度:94
語文別:中文
論文頁數:166
中文關鍵詞:樟芝輔助化療肝癌抗藥性
外文關鍵詞:Antrodia camphorateAdjuvant chemotherapiesHepatocellular carcinomaMultidrug resistance
相關次數:
  • 被引用被引用:4
  • 點閱點閱:1587
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:4
樟芝,學名Antrodia camphorata,別名有樟菇、樟菰、樟內菇、牛樟菇、紅樟、樟窟內菰等,為台灣特有之真菌,屬台灣特有種,先前文獻指出高濃度樟芝會對肝癌細胞造成毒殺效果,而且許多的研究報告都是給予樟芝後造成癌細胞凋亡,本實驗主要是探討樟芝對抗腫瘤細胞之輔助化療藥物角色。首先藉由細胞毒殺性分析篩選抗癌藥物,分別將抗癌藥物分成不同的族群(包括敏感、中度敏感、不敏感型),再合併使用對肝癌細胞無毒殺效果的樟芝濃度,觀察樟芝是否會改善肝癌細胞對抗癌藥物的敏感度,並探討其分子機制。低濃度樟芝可協同抗癌藥物抑制肝癌細胞存活率,是經由降低多藥抗藥性(Multidrug resistance;MDR)的產生,或是與抗癌藥物合併後加強其毒殺細胞作用,接著利用西方墨點法分析MDR路徑相關的蛋白質(例如:COX-2, Akt, PARP-1)。應用流式細胞儀技術檢測樟芝與抗癌藥物合併後是作用於細胞週期何處而引起細胞凋亡抑制肝癌細胞生長。
經由上述實驗發現肝癌細胞合併低濃度樟芝與不同作用機制的抗癌藥物後,調節肝癌細胞中多藥抗藥性(Multidrug resistance;MDR)相關蛋白的表現而使肝癌細胞抗藥性降低,造成藥物更易進入肝癌細胞中,因而增加了藥物累積量,同時也會降低P-gp作用以減少藥物排出量,最終使細胞走向凋亡一途。透過降低MDR表現同時促進抗癌藥物對細胞凋亡毒殺作用之結果推斷樟芝與抗癌藥物合併時是扮演一輔助性角色。
Antrodia camphorata (AC), a unique fungal species, used as a folk medicine in Taiwan. Hepatocellular carcinoma (HCC) is one of the most prevalent cancers, often respond with limited efficacy to currently available chemotherapeutics with multidrug resistance (MDR) expression. The present study were to establish an evaluation system on MDR, compare the adjuvant anti-cancer effects from ACs mycelia on the human hepatoma cell lines (HepG2, C3A and PLC/PRF/5),
which cause resistance to most chemotherapies.
The results indicated that cisplatin and paclitaxel can cause drug resistance and MDR-1 expression were positive on high dose (10M), while another (Mytomyocin) were more sensitivity and the MDR-1 expression were negative. Meanwhile, we found that diverse ACs on high dose also caused the cytotoxicity by MTT assay as well as the inhibition of MDR-1 expression by western blotting (100M) such as some chemotherapies induction above. Interestingly, the regiment of ACs treatment (<10M) combined with chemotherapies to HCC can potentate the anti-cancer activities and decreased MDR-1 expression, but ACs (>10M) treatment alone also induced the cytoxicity to normal liver cell (BNL).
Our data indicated that treated AC combined with chemotherapies can decrease MDR-1 expression through inhibition COX-2, P-Akt, and increase the PAPR-1 expression to HCC by western blotting. So, we believed that AC may play a important role of adjuvant chemotherapies to regulate MDR for HCC. Continuously, the cell cycle pase and apoptosis percentage (FACS) testing in vitro and in vivo model (ICR nude mice implanted liver tumor cells) to the effect of ACs with chemotherapies will be done.
中文摘要……………………………………………………………………………Ⅰ
Abstract…………………………………………………………………………Ⅲ
目次…………………………………………………………………………………Ⅴ
表目錄………………………………………………………………………………Ⅵ
圖目錄………………………………………………………………………………Ⅶ
縮寫對照表…………………………………………………………………………

第一章 文獻回顧……………………………………………………………………1
1.1樟芝簡介……………………………………………………………………1
1.1.1樟芝成分分析………………………………………………………4
1.1.2樟芝生理活性成分…………………………………………………5
1.1.3樟芝安全性相關試驗………………………………………………7
1.1.4樟芝功能性研究……………………………………………………9
1.2肝臟簡介……………………………………………………………………23
1.2.1肝癌簡介…………………………………………………………24
1.2.2肝癌病因……………………………………………………………28
1.2.3肝癌治療……………………………………………………………29
1.3多藥抗藥性…………………………………………………………………35
1.4腫瘤細胞多藥耐藥機制……………………………………………………36
1.5與多藥抗藥相關蛋白………………………………………………………48

第二章 研究動機與目的…………………………………………………………54

第三章 研究材料與方法…………………………………………………………56

第四章 結果與討論………………………………………………………………80

第五章 結論……………………………………………………………………102

第六章 結果圖表………………………………………………………………106

第七章 參考文獻………………………………………………………………157
Achenbach, T., Seifert, J.K., Pitton, M.B., Schunk, K., Junginger, T. (2002) Chemoembolization for primary liver cancer. Eur J Surg Oncol. 28: 37-41.
Adams, J.M., and Cory, S. (1998) The Bcl-2 Protein Family: Arbiters of Cell Survival. Science. 281: 1322-1326.
Allgaier, H.P., Galandi, D., Zuber, I., Blum, H.E. (2001) Radiofrequency thermal ablation of hepatocellular carcinoma. Dig Dis. 19: 301-310.
Allouche, M., Bettaieb, A., Vindis, C., Rousse, A., Grignon, C., and Laurent, G. (1997) Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin- induced apoptosis of leukemic cells. Oncogene. 14: 1837-1835.
Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I. and Gottesman, M.M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 39: 361-398.
angiogenic activities of polysaccharides isolated from Antrodia cinnamomea in endothelial cell. Life Sciences. 76: 3029-3042.
Asselin, E., Mills, G.B., Tsang, B.K. (2001) XIAP regulates Akt activity and caspase-3 -dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61: 1862-1868.
Asselin, E., Mills, G.B., Tsang, B.K. (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61: 1862-1868.
-associated protein, MRP. Eur. J. Cancer. 32A: 945-957.
Benn, J., Schneider, R.J. (1994) Hepatitis B virus HBx protein activates Ras- GTP complex formation and establishes a Ras, Raf, MAP Kinase signaling 19 cascade. Proc. Natl. Acad. Sci. USA. 91: 10350-10354.
Biedler, J. L., Reihm, H. (1970) Cellular resistance to Actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30: 1174-1179.
Biedler, J.L., Riehm, H. (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30: 1174-1184.
Borght, S.V. (2006) Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem. 18: 523-533.
Borst, P., Evers, R., Kool, M., Wijnholds, J. (2000) A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins. Journal of the National Cancer Institute. 92: 1295-302.
Bosh, I., Croop, J. (1996) P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta. 1288: F37-F54.
Bradley, G., Juranka, P. F., Ling, V. (1988) Mechanism of multidrug resistance. Biochim. Biophys. Acta. 948: 87-128.
Broxterman, H.J., Schuurhuis, G.J. (1997) Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J. Int. Med. 242: 147-151.
Brunetto, M.R., Oliveri, F., Rocca, G., Criscuolo, D., Chiaberge, E., Capalbo, M., David, E., Verme, G., Bonino, F. (1989) Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B antigen. Hepatology. 10: 198-202.
Caselmann, W.H., Meyer, M., Scholz, S., Hofschneider, P.H., Koshy, R. (1992) Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells. J Infect Dis. 166: 966-971.
Chang, H.L., Chen, C.C., Mau, J.L. (2001) Non-volatile taste components of Agaricus blazei, Antrodia camphorate and Cordyceps militaris mycelia. Food Chem. 74: 203-207.
Chang, T.T., Chou, W.N. (1995) Antrodia camphorate sp. Cinnomomum Kamehirai in Taiwan. Mycol. Res. 99: 756-8.
Chen, C.J., Yu, M.W., Liaw, Y.F. (1997) Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol & Hepatol. 12: S294-S308.
Cheng, J.J., Huang, N.K., Chang, T.T., Wang, D.L., Lu, M.K. (2005) Study for anti-
Chisari, F.V., Ferrari, C., Mondelli, M.U. (1989) Hepatitis B virus: Structure and biology. Microb Pathol. 6: 311-325.
Chu, G. (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269: 787-790.
Coffer, P.J., Woodgett, J.R. (1991) Molecular cloning and characterization of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 201: 475-481.
Davies, M.A., Koul, D., Dhesi, H., Berman, R., McDonnell, T.J., McConkey, D., Yung, W.K., Steck, P.A. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/ PTEN. Cancer Res. 59: 2551-2556.
Dempke, W., Rie, C., Grothey, A., Schmoll H.J. (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer. Res. Clin. Oncol. 127: 411-417.
Fantappie, O., Masini, E., Sardi, I., Raimondi, L., Bani, D., Solazzo, M., Vannacci, A., Mazzanti, R. (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology. 35: 843-852.
Ferrandina, G., Legge, F., Ranelletti, F.O., Zannoni, G.F., Maggiano, N., Evangelisti, A., Mancuso, S., Scambia, G., Lauriola, L. (2002) Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 95: 801-807.
Ferte, J. (2000) Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 267: 277-294.
Franco, D., Usatoff, V. (2001) Resection of hepatocellular carcinoma. Hepatogastroenterology. 48: 33-36.
Franke, T.F., Hornik, C.P., Segev, L., Shostak, G.A., Sugimoto, C. (2003) PI3K/Akt and apoptosis: size matters. Oncogene. 22: 8983-8998.
Germain, M.E.S., Gagnon, V., Parent, S., Asselin, E. (2004) Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Molecular Cancer. 3: 1-11.
Germann, U.A., Pastan, I., Gottesman, M.M. (1993) P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol. 4: 63-76.
Gibbs, J.B. (2000) Mechanism-based target identification and drug discovery in cancer research. Science. 287: 1969-1973.
Gilbert, L., Etwood, L., Merino, M., Masood, S., Barnes, R., Steinberg, S., Lazarus, D., Pierce, L.D.T., Moscow, J.A., Townsend, A.J., and Cowan, K.H. (1993) A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J. Clin. Oncol. 11: 49-58.
Glaccia, A.J., and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Devel. 12: 2973-2983.
Goldstein, L.G. (1997) MDR1 gene expression in solid tumors. Eur. J. Cancer. 32A
Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D.G., Mukhtar, H. (2000) Overexpression of cyclooxygenase-2 in human prostate denocarcinoma. Prostate. 42: 73-78.
Haince, J.F., Rouleau, M., Hendzel, M.J., Masson, J.Y., Poirier, G.G. (2005) Targeting poly(ADP-ri-bosyl)ation: a promising approach in cancer therapy. Trends Mol Med. 11: 456-463.
Hannun, Y.A. (1997) Apoptosis and the Dilemma of Cancer Chemotherapy. Blood. 89: 1845-1853.
Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., Murata, Y. (2000) Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 60: 5988-5994.
Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K.M. (1999) JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int. J. Cancer. 80: 417-424.
Higgins, C. F., Callaghan, R., Linton, K. J., Rosenberg, M.F., and Ford, R. C. (1997) Structure of the multidrug resistance P-glycoprotein. Sem. Cancer Biol. 8:135-142.
Hseu, Y.C., Wu, F.Y., Wu, J.J., Chen, J.Y., Chang, W.H., Lu, F.J., Lai, Y.C., Yang, H.L. (2005) Anti-inflammatory potential of Antrodia Camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-nB pathway. International immunopharmacology. 5: 1914-1925.
Huang, N.K., Cheng, J.J., Lai, W.L., Lu, M.K. (2005) Antrodia Camphorata prevents rat pheochromocytoma cells from serum deprivation-induced apoptosis. FEMS Microbiology Letters. 244: 213-219.
Hwang, G.Y., Chuang, Y.L., Huang, L.M., Wang, Y.H., Wang, J.C., Hsu, C.T., Yang, S.S., Wu, C.C. (2003) Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma. JOURNAL OF CLINICAL MICROBIOLOGY. 41: 5598–5603.
Isquierdo, M.A., van der Zee, A. G.J., Vermorken, J.B., van der Valk, P., Belien, J.A. M., Giaccone, G., Scheffer, G.L., Flens, M.J., Pinedo, H.M., Kenemans, P., Meijer, C.J.L.M., de Vrie, E.G.E., and Scheper, R.J. (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87: 1230-1237.
Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F., Hemmings, B.A. (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A. 88: 4171-4175.
Khamisy, S.F., Masutani, M., Suzuki, H., Caldecott, K.W. (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res . 31: 5526-5533.
Kip, A., West, S., Castillo, S., Phillip, A.D. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates. 5: 234-248.
Klein, N.P., Schneider, R.J. (1997) Activation of Src family of kinase by HBV HBx protein, and coupled signaling to Ras. Mol. Cell. Biol. 17: 6427-6436.
Koh, D.W., Dawson, T.M., Dawson, V.L. (2005) Mediation of cell death by poly polymerase-1. Pharmacol Res. 52: 5-1.
Kulkarni, S., Rader, J.S., Zhang, F., Liapis, H., Koki, A.T., Masferrer, J.L., Subbaramaiah, K., Dannenberg, A.J. (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 7: 429-434.
Lankelma, J., Luque, R.F.N., Dekker, Henk., Schinkel, W., Herbert, M., Pinedo (2002) Multistage hepatocarcinogenesis. Toxicology. 181: 43-47.
Leng, J., Han, C., Demetris, A.J., Georgr, K., Michalopoulos, Wu, Tong. (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: Evidence for AKT inhibition in Celecoxib-induced apoptosis. Hepatology. 3: 756-768.
Leppard, J.B., Dong, Z., Mackey, Z.B., Tomkinson, A.E. (2003) Physical and functional interact-ion between DNA ligase IIIalpha and poly(ADP-Ribose) polymerase 1 in DNA single-strand break repair. Mol Cell Biol. 23: 5919-5927.
Lin, D.Y., Lin, S.M., Liaw, Y.F. (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 12: 319-328.
List, A.F., Spier, C.G., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheper, R.J., Scheffer, G.L., and Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87: 2464-2469.
Loe, D.W., Deeley, R.G., and Cole, S.P.C.(1996)Biology of the multidrug resistance
Nagata, S. (1997) Apoptosis by death factor. Cell. 88: 355-365.
Nomura, F., Yaguchi, M., Togawa, A., Miyazaki, M., Isobe, K., Miyake, M., Noda, M., Nakai, T. (2000) Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol. 15: 529-535.
Nozaki, T., Fujihara, H., Watanabe, M., Tsutsumi, M., Nakamoto, K., Kusuoka, O., Kamada, N., Suzuki, H., Nakagama, H., Sugimura, T., Masutani, M. (2003) Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci. 94: 497 -500.
O’Connor, P.M., Jackman, J., Bai, I., Myers, T.G., Fan, S., Mutoh, M., Scudiero, D.A., Monks, A., Sausville, E.A., Weinstein, J., Friend, S., Fornace, A.J., and Kohn, K.W. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300.
Parks, R.W., Garden, O.J. (2001) Liver resection for cancer. World J Gastroenterol.7: 766-771.
Plagemann, P.G.W (1991) Hepatitis C virus. Arch. Virol. 120: 165-180.
Pommier, Y., Leteurte, F., Fesen, M.R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn K.W. (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542.
Poulaki, V., Mitsiades, C.S., Mitsiades, N. (2001) The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat. 4: 233-242.
Prasad, R., Lavrik, O.I., Kim, S.J., Kedar, P., Yang, X.P., Berg B.J.V., Wilson, S.H. (2001) DNA polymerase beta -mediated long patch base excision repair. Poly (ADP-ribose) polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem. 276: 32411-32414.
Qian, J., Feng, G.S., Vogl, T. (2003) Combined interventional therapies of hepatocellular carcinoma. World Journal of Gastroenterology. 9: 1885-1891.
Qu, J.H., Zhu,M.H., Lin, J., Ni, C.R., Li, F.M., Zhu, Z., Yu, G.Z. (2005) Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721. World Journal of Gastroenterology. 11(39): 6212-6215.
Reap, E.A., Roof, K., Maynor, K., Borrero, M., Booker, J., and Cohen, P.L. (1997) Radiation and stress-induced apoptosis; a role for Fas/Fas ligand interactions. Proc. Natl. Acad. Sci. USA. 94: 5750-5755.
Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., Harkonen, M. (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57: 1276-1280.
Roninson, I. B. (ed). (1990) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, N. Y.-London.
Rouleau, M., Aubin, R.A., Poirier, G.G. (2004) Poly(ADPribosyl)ated chromatin domains: access granted. J Cell Sci. 117: 815-825.
Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, S., Koi, T.Y., Onji, M., Ohta, Y., ChooQ, L., Houghton, M. Kuo, G. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 87: 6547-6549.
Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A. et al. (1995) The drug
resistance-related protein LRP is the human major vault protein. Nature Med. 1: 578-582.
Scheper, R.J. (1996) Major vault protein LRP-related multidrug resistance. Eur. J.
Cancer. 32A: 979-984.
Schepis, F., Verucchi, G., Pollicino, T., Attard, L., Brancatelli, S., Longo, G., Raimondo, G. (1997) Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. J Hepatol. 26: 765-770.
Schinkel, A.H. (1997) The physiological function of drug-transporting P-glycoproteins. Sem.Cancer Biol. 8: 161-170.
Seki, S., Sakaguchi, H., Kadoya, H., Morikawa, H., Habu, D., Nishiguchi, S., Shiomi, S., Kitada, T., Kuroki, T. (2000) Laparoscopic microwave coagulation therapy for hepatocellular carcinoma. Endoscopy. 32: 591-597.
Shao, J., Shen, H., Morrow, J.D., DuBois, R.N. (2000) Regulaton of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biool. Chem. 275: 33951-33956.
Shao, J., Sheng, H., Inoue, H., Morrow, J.D., DuBois, R.N. (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem. 275: 33951-33956.
Simon, S. M., Schindler, M. (1994) Cell Biological Mechanisms of Multidrug Resistance in Tumors. Proc. Natl. Acad. Sci. USA. 91: 3497-3504.
Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Siderivski, D.P., and Mak, T.W. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95: 29-39.
Stavrovskaya, A.A. (2000) Cell Mechanisms of Multidrug Resistance of Tumor Cells. Biochemistry (Moscow). 65: 112-126.
Stein, U., Walther, W., Laurencot, C.M., Scheffer, G.L., Scheper, R.J., Shoemaker, R.H. (1997) Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst. 89: 807-813.
Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G.F., Holmes, A.B., Gaffney, P.R., Reese, C.B., McCormick, F., Tempst, P., Coadwell, J., Hawkins, P.T. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 279: 710-714.
Sturm, J.W., Keese, M.A., Bonninghoff, R.G., Wustner, M., Post, S. (2001) cally ablative therapies of hepatocellular carcinoma. World J Gastroenterol. 24(Suppl 5): 35-45.
Tang, Z.Y. (2001) Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol. 7: 445-454.
Tasi, Z., Liaw, S. (1985) The Use and the Effect of Ganoderma.San Yun Press. Taichung. Taiwan.
Tew, K.D. (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54: 4313-4320.
Toffoli, G., Frustaci, S., Tumiotto, L., Gherlizoni, F., Picci, P., and Boicci, G. (1992) Expression of MDR1 and GST- in human soft tissue sarcomas: Relation to drug resistance and biological aggressiveness. Ann. Oncol. 3: 63-69.
Tsutsumi, M., Masutani, M., Nozaki, T., Kusuoka, O., Tsujiuchi, T., Nakagama, H., Suzuki, H., Konishi, Y., Sugimura, T. (2001) Increased susceptibility of poly(ADPribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis. 22: 1-3.
Vimal, A., Patel, Michael, J., Dunn, Sorokin, A. (2002) Regulation of MDR-1(P-glycoprotein) by Cyclooxygenase-2. The Journal of Biological Chemistry. 277: 38915-38920.
Wang, Y., Blandino, G., Oren, M., and Givol, D.O. (1998) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Oncogene. 17: 1923-1930.
WARIS, G., SIDDIQUI, A. (2003) Regulatory mechanisms of viral hepatitis B and C. J. Biosci. 28: 311-321.
Wu, M.C., Shen, F. (2000) Progress in research of liver surgery in China. World J Gastroenterol. 6: 773-776.
Wu, Q.L., Wu, X.P., Liang, Y.J., Chen L.M., Yan, D., Fu, L.W. (2005) P-glycoprotein is not involved in pathway of anti-Fas/Fas-induced apoptosis in KBv200 cells. World J Gastroenterol. 11: 3544-3548.
Yang, H.L., Chen, C.S., Chang, W.H., Lu, F.J., Lai, Y.C., Chen, C.C., Hseu, T.H., Kuo,
C.T., Hseu, Y.C. (2006) Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorate. Cancer Letters. 231: 215-227.
Yu, S.W., Wang, H., Poitras, M.F., Coombs, C., Bowers, W.J., Federoff, H.J., Poirier, G.G., Dawson, T.M., Dawson, V.L. (2002) Mediation of poly(ADP-ribose) polymerase -1- dependent cell death by apoptosis-inducing factor. Science. 297: 259-263.
Yun, C., Cho, H., Kim, S.J., Lee, J.H., Park, S.Y., Chan, G.K., Cho, H. (2004) Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res. 2: 159-169.
http://www.doh.gov.tw/statistic/data/死因摘要/95年/統計圖/5.主要癌症死亡率.xls,行政院衛生署,民國95年死因統計資料。
吳昇原,2002,牛樟抽出物對樟芝生長影響之探討,國立台灣大學森林學研究所碩士論文。
吳昭新,1995,肝臟病,理藝出版社,新竹市。
吳家駒、盧珍炆、洪鳴遠、黃瑞玉、陳如茵、蔡美珠,2003,臺灣農業化學與食品科學雜誌,41,268
呂美津,2002,牛樟菇子實體乙醇萃取物誘導HL60 細胞凋亡之研究,屏東科技大學熱帶農業暨國際合作研究所碩士論文。
宋祖瑩,2003,樟芝深層培養液抗氧化及抗腫瘤之特性,國立中興大學食品科學研究所博士論文
宋瑞樓,林毓萌,方唯則,辜公亮基金會和信治癌中心醫院,和信醫院與您(肝癌專輯),2001.4.1(13)。
李一宏,2003,樟芝菌絲體之培養及其多醣體抗乙型肝炎病毒活性評估,中國醫藥大學中國藥學研究所博士論文。
李貞宜,2005,樟芝保肝作用之探討,南台科技大學生物科技研究所碩士論文。
李炫璋,2002,牛樟芝菌絲體之體內保肝功能評估及其熱水萃物在體外對基質金屬蛋白水解酶活性之影響國立中興大學食品科學研究所碩士論文。
林加進,2002,台灣地區B型肝炎病毒、C型肝炎病毒與其他輔助因子致肝細胞癌危險性之社區性長期追蹤研究,國防大學國防醫學院公共衛生學研究所碩士論文。
林金鑫、曾虹萍、陳勁初、蔡明憲、陽明芬、陳巧文,2001,大鼠致畸變測試-樟芝發酵原液凍乾成品,中華保健營養學會。
林苡芬,2004,不同發酵碳源之牛樟芝菌絲體發酵過濾液對人類肝癌細胞株之影響,國立台灣大學食品科技研究所碩士論文。
林艷琪,2005,樟芝固態培植體之成分分析及功能性評估,南台科技大學生物科技研究所碩士論文。
范真綺,2003,樟芝固態栽培與液態發酵菌絲體之成分及其生物活性之研究,南台科技大學化學工程研究所碩士論文。
高曉薇,1991,台灣靈芝屬新種樟芝之三萜類成份研究,台北醫學院天然物醫學研究所碩士論文。
張中姿,2002,樟芝菌絲體之甲醇萃取部分對人類肝癌細胞株(HepG2)生長抑制作用的機轉探討,國立臺灣大學生物化學暨分子生物學研究所碩士論文。
張怡婷,2004,樟芝抗腫瘤活性之研究,國立成功大學藥理學研究所碩士論文。
張東柱,1997,牛樟芝病害,牛樟生物學及育林技術研討會論文集,林業叢刊第72號:127-131。
張紹欣,2003,天然食材的樟芝發酵產物對抑制腫瘤細胞之評估,南台科技大學化學工程研究所碩士論文。
許 駿,2004,肝細胞癌藥物治療之研究,國立台灣大學醫學院臨床醫學研究所博 士倫文。
許勝傑、鍾煒惠、陳勁初、蔡明憲、王聖耀、蔡慶隆、陳巧文,2001,大白鼠口服高劑量樟芝菌絲體之急性毒性試驗,中華保健營養學會。
郭育君,2005,樟芝子實體乙酸乙酯層及玫瑰樹鹼對肝癌細胞株HepG2 和PLC/
PRF/5 之活性與其作用機轉之探討,高雄醫學大學天然藥物研究所碩士論文。
郭淑卿,2001,樟芝發酵液對大鼠肝臟纖維化及胃腸功能之改善作用,中國醫藥大學營養學研究所碩士論文。
陳心慧,2004,牛樟芝不同極性區分保肝機能性之研究,中國醫藥大學營養學研究所 碩士論文。
陳伯珠,2004,一、高通量篩選出牛樟芝菌絲體抗肝炎先導藥物化合物;二、以p53、bax、bcl-2之m-RNA層次進行抗肝癌先導藥物化合物對人類肝癌細胞株 HepG2凋亡途徑之探討,國立中正大學化學研究所碩士論文。
陳怡欣,2001,牛樟芝發酵過濾液對大白鼠肝臟生理機能之影響,中國醫藥大學營養學研究所碩士論文。
陳政憲,2005,樟芝清除香菸萃取液之自由基及抑制平滑肌細胞氧化傷害,朝陽科技大學應用化學系研究所碩士論文。
陳勁初、呂鋒洲,2002,靈芝之王:台灣樟芝,元氣齋出版社。
陳啟楨、蘇慶華、藍明煌,2001,中華真菌協會會刊第十六卷,第一、二期。
陳清農、林文鑫、盛莉莎、黃仕政、陳勁初、劉宗榮,2001,樟芝對 Sprague-Dawley 大白鼠之連續投藥口服急性中毒,中華保健營養學會。
程一華,1994,樟芝之成份研究,國立台灣師範大學化學研究所碩士論文。
黃仕政,2005,蛹蟲草之培養和其呈味性質及經γ-照射之巴西蘑菇子實體和樟芝菌
絲體之抗氧化性質,國立中興大學食品科學研究所博士論文。
黃坤正、丁懷謙、余俊強、何漣漪,基因毒理與動物病理組織之系統分析,依「食品新興製造系統整合及關鍵技術開發四年計劃(第四年度)」2000計劃標號007051-04:3-12
黃玲娟,2000,樟芝和姬松茸之組成分析及構型鑑定,國立中興大學食品科學研究所碩士論文。
黃惟敏,1999,樟芝微量成分的研究(Ⅱ),靜宜大學應用化學系研究所碩士論文。
葉怡真,2002,樟芝對血管內皮細胞之影響及保心血管疾病之機制探討,中國醫藥大學營養學研究所碩士論文。
廖英明,1998,菇類中的許不了-樟芝,農業世界雜誌,176:76-79。
臧穆、蘇慶華,1990,我國台灣產靈芝屬新種-樟芝(型態、定名),雲南植物研究所,12(4):395-6。
劉俊仁,2003,中草藥抗癌機制研究:(壹):黃芩素及黃芩苷對血管新生作用之影響及其機制探討;(貳): 樟芝活性多醣體之生物活性分析及其經由免疫調節抑制腫瘤生長之研究,國立臺灣大學生物化學暨分子生物學研究所博士論文。
劉翠玲,2001,樟芝對倉鼠體內脂質代謝與抗氧化狀態之影響,輔仁大學食品營養學研究所碩士論文。
潘致良,2004,利用蛋白質體探討樟芝萃取物處理在人類肺癌細胞株(A549),南台科技大學生物科技研究所碩士論文。
蔡育真,2005,固態發酵樟芝對小鼠免疫調節及抗腫瘤,南台科技大學生物科技研究所碩士論文。
蔡雁輝,2002,樟芝深層培養液及其多醣體之抗氧化特性,國立中興大學食品科學研究所碩士論文。
盧祉彤,2004,牛樟芝菌體對腫瘤細胞的影響,南台科技大學生物科技研究所碩士論文。
賴鈺菁,2004,樟芝發酵液之抗發炎及其誘導癌細胞凋亡機制之探討,中國醫藥大學營養學研究所碩士論文。
魏佳瑜,2003,固體栽培樟芝甲醇萃取物抗變異自由基功效與抗血小板凝集作用探討,台北醫學大學公共衛生學研究所碩士論文。
嚴貴榮,2002,樟芝對STZ誘發高血糖鼠血糖調節與抗氧化之影響,輔仁大學食品營養學研究所碩士論文。
蘇慶華,2002,健康的守護神(國寶樟芝),愛克思文化事業有限公司。台北,台灣,38-39。
連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔